Evidence map›Paper›PMID 37945971›Full record

ArticleMolecular imaging and biology2024

SOX71, A Biocompatible Succinyl Derivative of the Triarylmethyl Radical OX071 for In Vivo Quantitative Oxygen Mapping Using Electron Paramagnetic Resonance.

Misa A Shaw, Martin Poncelet, Navin Viswakarma, Gian Paolo Vallerini, Safa Hameed, Teresa D Gluth, Werner J Geldenhuys, Emily H Hoblitzell, Timothy D Eubank, Boris Epel and 2 more

Open access · greenAbstract read
In one paragraph

Article in Molecular imaging and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. What Is the Information Content of EPR Oximetry?Advances in experimental medicine and biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Misa A Shaw *Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA.
Martin Poncelet *Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA.
Navin ViswakarmaOxygen Measurement Core, O2M Technologies, LLC, Chicago, IL, 60612, USA.
Gian Paolo ValleriniOxygen Measurement Core, O2M Technologies, LLC, Chicago, IL, 60612, USA.
Safa HameedOxygen Measurement Core, O2M Technologies, LLC, Chicago, IL, 60612, USA.
Teresa D GluthDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA.
Werner J GeldenhuysDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA.
Emily H HoblitzellDepartment of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, Morgantown, WV, 26506, USA.
Timothy D EubankIn Vivo Multifunctional Magnetic Resonance Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV, 26506, USA.
Boris EpelDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, 60637, USA.
Mrignayani KotechaOxygen Measurement Core, O2M Technologies, LLC, Chicago, IL, 60612, USA. mkotecha@oxygenimaging.com.
Benoit DriesschaertDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA. Benoit.driesschaert@hsc.wvu.edu.ORCID 0000-0002-1402-413X
West Virginia University · USSOS Oxygène (France) · FRUniversity of Chicago · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI Travis Salisbury · 2012 to 2026
$61.1M
WVU Flow Cytometry and Single Cell Core Facility (FCSCCF)P20GM121322 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Dominique Bollino · 2018 to 2026
$22.4M
VS-CoBRE Administrative CoreP20GM144230 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Shian Liu · 2022 to 2026
$13.9M
Cell and Molecular Biology Training Program at West Virginia UniversityT32GM133369 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Zoica Cerasela Dinu, MICHAEL D SCHALLER · 2019 to 2026
$2.0M
Biocompatible triarylmethyl radical-based dendrimers as nonmetallic contrast agents for MRIR01EB032321 · NIBIB · WEST VIRGINIA UNIVERSITY · PI DRIESSCHAERT, BENOIT · 2022 to 2025
$1.5M
Biocompatible Magnetic Resonance Probes for in vivo Concurrent Profiling R00EB023990 · NIBIB · WEST VIRGINIA UNIVERSITY · PI DRIESSCHAERT, BENOIT · 2019 to 2021
$730k
Imaging enzyme activity by Overhauser-enhanced MRIR21EB028553 · NIBIB · WEST VIRGINIA UNIVERSITY · PI DRIESSCHAERT, BENOIT · 2020 to 2022
$599k
Electron Spin Resonance Microfluidics as a new tool in chemical single cell population analysisR21GM143595 · NIGMS · WEST VIRGINIA UNIVERSITY · PI BLANK, AHARON, DRIESSCHAERT, BENOIT · 2022 to 2023
$387k
NIBIB NIH HHS R00 EB023990NIBIB NIH HHS R01 EB032321NIBIB NIH HHS R21 EB028553NIGMS NIH HHS GM133369NIGMS NIH HHS GM143595NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P20GM103434NIGMS NIH HHS P20 GM121322NIGMS NIH HHS P20GM121322NIGMS NIH HHS P20 GM144230NIGMS NIH HHS P20GM144230NIGMS NIH HHS R21 GM143595NIGMS NIH HHS T32 GM133369NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

purposeThis study aimed to develop a biocompatible oximetric electron paramagnetic resonance (EPR) spin probe with reduced self-relaxation, and sensitivity to oxygen for a higher signal-to-noise ratio and longer relaxation times at high oxygen concentration, compared to the reference spin probe OX071. PROCEDURES: SOX71 was synthesized by succinylation of the twelve alcohol groups of OX071 spin probe and characterized by EPR at X-Band (9.5 GHz) and at low field (720 MHz). The biocompatibility of SOX71 was tested in vitro and in vivo in mice. A pharmacokinetic study was performed to determine the best time frame for EPR imaging. Finally, a proof-of-concept EPR oxygen imaging was performed on a mouse model of a fibrosarcoma tumor.

resultsSOX71 was synthesized in one step from OX071. SOX71 exhibits a narrow line EPR spectrum with a peak-to-peak linewidth of 66 mG, similar to OX071. SOX71 does not bind to albumin nor show cell toxicity for the concentrations tested up to 5 mM. No toxicity was observed after systemic delivery via intraperitoneal injection in mice at twice the dose required for EPR imaging. After the injection, the probe is readily absorbed into the bloodstream, with a peak blood concentration half an hour, post-injection. Then, the probe is quickly cleared by the kidney with a half-life of ~ 45 min. SOX71 shows long relaxation times under anoxic condition (T

conclusionSOX71, a succinylated derivative of OX071 was synthesized, characterized, and applied for in vivo EPR tumor oxygen imaging. SOX71 is highly biocompatible, and shows decreased sensitivity to oxygen and self-relaxation. This first report suggests that SOX71 is superior to OX071 for absolute oxygen mapping under a broad range of pO

Indexed as

OxygenAnimalsBiocompatible MaterialsCell Line, TumorElectron Spin Resonance SpectroscopyHumansMiceSpin LabelsBiocompatible MaterialsOxygenSpin LabelsEPRImagingOxygenSpin probesTriarylmethylTrityl

Identifiers

PMID37945971
PMCPMC11078887
OpenAlexW4388540952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.